{"commentary":{"count":83,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":65,"podcast":12,"youtube":6},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01726452\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT01726452","nct_id":"NCT01726452","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct01726452. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Modified MAGIC: The modified MAGIC regimen encompasses 3 cycles of chemotherapy pre-surgery and 3 cycles post-surgery. The regimen is a combination of epirubicin, cisplatin or oxaliplatin and a choice of 5-fluorouracil or capecitabine. Each cycle lasts 21 days.\n\nFLOT: The FLOT regimen encompasses 8 cycles of chemotherapy in total , 4 cycles of chemotherapy pre-surgery and a further 4 cycles of chemotherapy post-surgery. Each cycle of chemotherapy lasts 14 days/2 weeks.","label":"A (Modified MAGIC) OR Arm A: FLOT","type":"EXPERIMENTAL"},{"description":"Arm B consists of the multimodal CROSS arm, which includes a combination of chemotherapy and radiotherapy prior to surgery. The patient will receive four and a half (4.5) weeks of radiation therapy (41.4 Gy/23 fractions), and 5 weekly cycles of chemotherapy. The chemotherapy and radiotherapy will run concurrently over a 4 and a half-week period. Chemotherapy is given by intravenous infusion on days 1, 8, 15, 22 and 29. The radiation will generally commence on the 1st day of treatment and will run for 4 and a half weeks as follows: days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31 inclusive.","label":"B (CROSS)","type":"EXPERIMENTAL"}],"collaborators":["Southampton Clinical Trials Unit","Copenhagen University Hospital, Rigshospitalet","Centre Hospitalier Régional, Universitaire de Lille"],"completion_date":{"date":"2022-08-04","type":"ACTUAL"},"conditions":["Adenocarcinoma of the Oesophagus","Adenocarcinoma of the Oesophago-gastric Junction","Oesophageal Tumours","Junctional Tumours","Oesophageal Cancer"],"enrollment":{"count":377,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Epirubicin","type":"DRUG"},{"name":"Cisplatin / Oxaliplatin","type":"DRUG"},{"name":"5 Flourouracil/ Capecitabine","type":"DRUG"},{"name":"(41.4 Gy/23 fractions)","type":"RADIATION"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Docetaxel","type":"DRUG"},{"name":"Oxaliplatin","type":"DRUG"},{"name":"Leucovorin","type":"DRUG"},{"name":"5-Fluorouracil","type":"DRUG"}],"last_update":"2022-09-30","lead_sponsor":"Cancer Trials Ireland","official_title":"Neo-AEGIS (NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study): Randomised Clinical Trial of Neoadjuvant and Adjuvant Chemotherapy (Modified MAGIC or FLOT Regimen) vs. Neoadjuvant Chemoradiation (CROSS Protocol) in Adenocarcinoma of the Oesophagus and Oesophago-gastric Junction","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2022-08-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"At end of trial- up to 3 years in follow up"}],"references":[{"citation":"Reynolds JV, Preston SR, O'Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Parker I, Risumlund SL, Roy R, Falk S, Hanna GB, Bartlett FR, Alvarez-Iglesias A, Achiam MP, Nilsson M, Piessen G, Ravi N, O'Toole D, Johnston C, McDermott RS, Turkington RC, Wahed S, Sothi S, Ford H, Wadley MS, Power D; Neo-AEGIS Investigators and Trial Group. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):1015-1027. doi: 10.1016/S2468-1253(23)00243-1. Epub 2023 Sep 18.","pmid":"37734399","type":"DERIVED"},{"citation":"Reynolds JV, Preston SR, O'Neill B, Baeksgaard L, Griffin SM, Mariette C, Cuffe S, Cunningham M, Crosby T, Parker I, Hofland K, Hanna G, Svendsen LB, Donohoe CL, Muldoon C, O'Toole D, Johnson C, Ravi N, Jones G, Corkhill AK, Illsley M, Mellor J, Lee K, Dib M, Marchesin V, Cunnane M, Scott K, Lawner P, Warren S, O'Reilly S, O'Dowd G, Leonard G, Hennessy B, Dermott RM. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer. 2017 Jun 3;17(1):401. doi: 10.1186/s12885-017-3386-2.","pmid":"28578652","type":"DERIVED"}],"start_date":{"date":"2013-01-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)","url":"https://clinicaltrials.gov/study/NCT01726452"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct01726452"}